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Abstract
Osteosarcoma (OS) is the most common primary bone tumor that primarily affects children and adolescents. Studies
suggested that dysregulation JAK/STAT signaling promotes the development of OS. Cells treated with pimozide, a
STAT5 inhibitor suppressed proliferation and colony formation and induced sub G0/G1 cell cycle arrest and apoptosis.
There was a reduction in cyclin D1 and CDK2 expression and Rb phosphorylation, and activation of Caspase-3 and
PARP cleavage. In addition, pimozide suppressed the formation of 3-dimensional osteospheres and growth of the cells
in the Tumor in a Dish lung organoid system. Furthermore, there was a reduction in expression of cancer stem cell
marker proteins DCLK1, CD44, CD133, Oct-4, and ABCG2. More importantly, it was the short form of DCLK1 that was
upregulated in osteospheres, which was suppressed in response to pimozide. We further conﬁrmed by ﬂow cytometry
a reduction in DCLK1+ cells. Moreover, pimozide inhibits the phosphorylation of STAT5, STAT3, and ERK in OS cells.
Molecular docking studies suggest that pimozide interacts with STAT5A and STAT5B with binding energies of −8.4
and −6.4 Kcal/mol, respectively. Binding was conﬁrmed by cellular thermal shift assay. To further understand the role
of STAT5, we knocked down the two isoforms using speciﬁc siRNAs. While knockdown of the proteins did not affect
the cells, knockdown of STAT5B reduced pimozide-induced necrosis and further enhanced late apoptosis. To
determine the effect of pimozide on tumor growth in vivo, we administered pimozide intraperitoneally at a dose of
10 mg/kg BW every day for 21 days in mice carrying KHOS/NP tumor xenografts. Pimozide treatment signiﬁcantly
suppressed xenograft growth. Western blot and immunohistochemistry analyses also demonstrated signiﬁcant
inhibition of stem cell marker proteins. Together, these data suggest that pimozide treatment suppresses OS growth
by targeting both proliferating cells and stem cells at least in part by inhibiting the STAT5 signaling pathway.

Introduction
Osteosarcoma (OS) is the most common pediatric bone
malignancy in the world and the eighth most common
childhood cancer. Incidence of OS is 4.4 per million per
year from birth to 24 years of age1. While only 20% of
patients present with metastasis that is clinically
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detectable, the majority of the remaining 80% are presumed to have undetectable micrometastases at diagnosis,
primarily in the lung2. The ﬁve-year overall survival for
metastatic OS ranges from 20–40%. Current therapy
includes surgery and chemotherapy. Traditional chemotherapeutic agents have included high dose methotrexate, cisplatin, doxorubicin, and ifosfamide3. While
chemotherapy has increased overall survival in localized
OS, survival rates have remains stagnant for the last
30–40 years4. Moreover, only 30% of patients with
metastatic OS achieve long-term survival. For those who
have recurrent disease, prognosis is poor with postrelapse survival of less than 20%5. Due to limited success
of surgical resection and systemic chemotherapy for
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metastatic OS, there is a need to evaluate new treatment
regimens that could potentially offer increased cure and
survival in these afﬂicted patients.
Studies speculate that the antipsychotic medications may
also provide antineoplastic effects against cancers. Pimozide
(Fig. 1a) is an FDA-approved cell-permeable and orally
available drug belonging to the diphenylbutylpiperidine
class that has been regularly used for treating schizophrenia
and Tourette syndrome6. In the anterior pituitary, the
compound functions by binding to the dopamine receptor
D2 resulting in a decrease in the dopamine neurotransmission and serum elevation of the hormone prolactin7. Pimozide has also demonstrated the ability to inhibit
cancer growth in neuroblastoma, lymphoblastoma, breast
cancer, and non-small cell lung cancers8.
Janus Kinases (JAK) are a family of cytoplasmic tyrosine
kinases essential in the signaling cascade for cytokines and
growth factors9. Upon being phosphorylated, JAK can
activate a family of transcription factors known as signal
transducer and activator of transcription (STAT). Upon
being phosphorylation, STAT will translocate from the
cytoplasm to the nucleus where it can mediate transcription of target genes involved in proliferation, differentiation, and survival10. Pimozide has been shown to
inhibit the constitutive STAT5 Tyr694 phosphorylation,
although the mechanism of this inhibition is currently
unknown10,11.
Recent studies supporting the presence of cancer stem
cells (CSCs) have led to efforts to identify and develop
therapeutic strategies targeting these cells12. In addition, it
has been shown that CSCs are highly resistant to standard
therapy13. Stemness-related markers in OS are ABCG2,
Nestin, CD44, STRO-1, and Endoglin/CD10514–17. Previously, we identiﬁed a novel protein doublecortin
calmodulin-like kinase 1 (DCLK1) that is present in
reserve quiescent stem cells in both the normal intestinal
epithelium and in colon cancers18,19. Moreover, the
majority of human colon cancers was shown to express
the short form of DCLK120. Studies conﬁrmed that
DCLK1 distinguishes between tumor and normal stem
cells in the intestine and could be therapeutic target for
colon cancer21,22. In OS, mesenchymal stem cells have
been shown to induce IL-6 expression, which then activates the JAK/STAT signaling pathway by binding to their
cognate receptor in OS cells. Moreover, blocking STAT3
activation using an IL-6 neutralizing antibody resulted in
decreased cell proliferation, migration, and cell death of
the cancer cells23. Studies suggested that blocking the
JAK/STAT pathway is therefore a potential option for OS
treatment24,25. One study has suggested that targeting
growth hormone stimulated STAT5 activation results in
decreased STAT5 transcriptional activity26. In this report,
we have determined the effect of pimozide on STAT5,
and on OS cell growth and stemness.
Ofﬁcial journal of the Cell Death Differentiation Association
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Results
Pimozide inhibits OS cell growth

We ﬁrst determined the effect of pimozide (Fig. 1a) on
proliferation of various cultured OS cell lines. Pimozide
inhibits proliferation of KHOS/NP, MG63, and SJSA-1 in
a dose and time dependent manner (Fig. 1b). This antiproliferative effect on the OS cells was initially seen within
a 24 h period, and this effect continued to signiﬁcantly
increase over the next 72 h. The inhibitory constant value
at 48 h in KHOS/NP, MG63, and SJSA-1 cell lines was
determined to be 8.5, 10, and 9 µM, respectively (Fig. 1b).
To determine the long-term effect of pimozide treatment,
we treated the OS cells with 10 µM pimozide for 48 h.
Thereafter, the pimozide was removed and the cells were
allowed to grow and form colonies. Treatment with
pimozide resulted in signiﬁcantly reduced number of
colonies in all three OS cell lines (Fig. 1c). This suppression suggests the irreversible effect of pimozide on the
OS cells. To further demonstrate that the compound
affects OS cells and not normal cells, we performed studies in the multicell type lung organoid model (called
TiD)27. The TiD organoid contains immortalized lung
epithelial and ﬁbroblasts, along with endothelial cells
thereby creating a in vivo-like tumor microenvironment
providing the necessary cell-cell contact, architecture, and
inﬂuence of different cell types for the OS cells27. We
generated TiDs with OS cells which were labeled with
GFP. When the TiD was treated with 20 µM pimozide,
there was a signiﬁcant reduction in growth of the OS cells
without affecting the normal cells (Fig. 1d, e). These data
suggest the compound affects growth of OS cells, without
affecting normal cells.
Pimozide induces G0/G1 cell cycle arrest and apoptosis in
OS cells

Given that the Pimozide inhibits proliferation and colony formation; we next determined whether the compound affects cell cycle progression. For this, we chose
two cell lines KHOS/NP and SJSA-1. Treatment with
pimozide signiﬁcantly increased G0/G1 and sub-G0 arrest
in both KHOS/NP and SJSA-1 cells (Fig. 2a). This was
observed when the cells were treated with pimozide for
either 24 h or 48 h. Next, we determined whether pimozide induces apoptosis in OS cell lines. For this, we treated
the cells with 10 or 20 µM pimozide for 24 h and 48 h,
following which we ﬁrst determined caspase 3/7 activity
using a ﬂuorescence-based assay. Treatment with pimozide signiﬁcantly increased caspase 3/7 activity in both
KHOS/NP and SJSA-1 cells (Fig. 2b, Supplementary Fig.
1a). These results were further conﬁrmed by western
blotting for caspase 3 activation and PARP cleavage.
Again, pimozide treatment demonstrated increased levels
of cleaved caspase 3 and PARP proteins in both KHOS/
NP and SJSA-1 cells (Fig. 2c).
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Fig. 1 Pimozide inhibits osteosarcoma growth. a Pimozide structure. b KHOS/NP, MG63, and SJSA-1 cells were incubated with increasing doses of
pimozide (0–40 μM), and cell proliferation was determined. Pimozide treatment resulted in a signiﬁcant dose-and time-dependent decrease in cell
proliferation in all cell lines when compared with controls. c KHOS/NP, MG63, and SJSA-1 cells were incubated with 10 µM pimozide for 48 h and the
cells were allowed to grow and form colonies. Pimozide treatment inhibits colony formation. Results are representative of three independent
experiments. d and e Pimozide at 20 μM concentration speciﬁcally inhibits the growth of KHOS/NP GFP positive cells, but not the normal cells in the
TiD system. Scale bars represent 100 μm.
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Fig. 2 Pimozide induces cell cycle arrest and apoptosis. a Cell cycle analysis of pimozide treated cells. KHOS/NP and SJSA-1 were treated with
20 µM of pimozide for 24 and 48 h and then examined by ﬂow cytometry following propidium iodide staining for DNA content. Pimozide treatment
increased SubG0/G1 arrest at 24 and 48 h in both cells. b Cells were incubated with pimozide 10 and 20 µM concentration for 24 h and assessed for
apoptosis by Caspase3/7 assay. Pimozide treatment results in signiﬁcant increase in caspase-3/7 activity in both KHOS/NP and SJSA-1 cells (*p <
0.001). c Cells were treated with 20 μM of pimozide for 24 and 48 h, the lysate was analyzed by western blotting for Caspase 3 and PARP protein
expression. Both the cell lines showed caspase 3 cleavage and PARP cleavage following pimozide treatment. d Lysates from cells incubated with
20 µM of pimozide were analyzed by western blotting for cyclin D1, along with CDK2 and phosphorylation of RB levels. Pimozide inhibits cyclin D1,
CDK2 expressions and phosphorylation of RB levels in both KHOS/NP and SJSA-1 cells. e Cells were treated with 20 μM of pimozide for 24 and 48 h,
the lysate was analyzed by western blotting for anti-apoptotic and pro-apoptotic proteins. Pimozide treatment resulted in decreased levels of Bcl2
and Bcl-XL expression and increased Bax expression in both KHOS/NP and SJSA-1 cells.
Ofﬁcial journal of the Cell Death Differentiation Association
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Cyclin D1 is a cell cycle regulatory protein that regulates
the G1 to S-phase transition of the cell cycle. Cyclin D1
overexpression has been linked to the development and
progression of cancer28. Pimozide treatment inhibited
cyclin D1 expression (Fig. 2d). In addition, we performed
western blots to determine levels of the G0/G1 cell cycle
marker protein CDK2 and phosphorylation of retinoblastoma protein (Rb). Pimozide treatment signiﬁcantly
reduced CDK2 expression, as well as phosphorylation of
Rb in both KHOS/NP and SJSA-1 cells (Fig. 2d). In
addition, we also performed western blot for CDK4 and
CDK629. Pimozide treatment signiﬁcantly reduced CDK4
and CDK6 expression in both KHOS/NP and SJSA-1 cells
(Supplementary Fig. 1b). We next determined whether the
pimozide induces apoptosis by performing western blot
analyses for the anti-apoptotic proteins Bcl2 and Bcl-XL,
and pro-apoptotic protein Bax. Pimozide reduced Bcl2
and Bcl-XL levels, whereas there was a signiﬁcant increase
in Bax protein levels in both KHOS/NP and SJSA-1 cells
(Fig. 2e). These data suggest that pimozide induces
apoptosis.
Pimozide inhibits stemness

Deﬁning the mechanisms that regulate stem cell fate is
critical to increase our understanding of the neoplastic
process. CSCs are capable of self-renewal and generating
tumors resembling the primary tumor30,31. We ﬁrst
determined the effects of pimozide on sphere-formation
assay, a well-accepted biological property representing
stemness. Treatment of OS cells with pimozide signiﬁcantly inhibited osteosphere formation in KHOS/NP
and SJSA-1 cells (Fig. 3a, b top panel). To conﬁrm the
reduction was due to loss of stem cells, primary spheroids
were dissociated, and the equal number of cells were
reseeded without any additional pimozide. There was a
further reduction in secondary spheroid formation in the
pimozide treatment group (Fig. 3b bottom panel). To
conﬁrm the effect on CSCs, we next determined the effect
of pimozide on the expression of stem cell marker proteins. Previously, we and others had identiﬁed the protein
Doublecortin-like kinase 1 (DCLK1) to be a reserve
quiescent stem cells in both the normal intestinal epithelium and in colon cancers18,19. Further studies conﬁrmed that DCLK1 distinguishes between tumor and
normal stem cells in the intestine and could be therapeutic target for colon cancer21,22. DCLK1 has been
shown be expressed in two forms, a full-length large form
that encodes two microtubule-associating DCX domains
at the N-terminus and a calmodulin-like kinase domain at
the C-terminus. In addition, a shorter variant of the
protein is expressed that lacks the N-terminal DCX
domain32–35. To determine whether DCLK1 is expressed
in OS cells, we performed western blot analyses of
extracts generated from cells grown in 2-dimensional
Ofﬁcial journal of the Cell Death Differentiation Association
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(2D) monolayer and 3-dimensional (3D) spheroid cultures. There was expression of the long and short form of
DCLK1 in both KHOS/NP and SJSA-1 cells (Fig. 3c, d).
Furthermore, the two isoforms of the protein were
upregulated in 3D osteospheres of both KHOS/NP and
SJSA-1 cells (Fig. 3c, d). Moreover, following pimozide
treatment, there was greater decrease in the shorter isoform of the protein. Further conﬁrmation of reduction
was obtained by ﬂow cytometry demonstrating reduced
numbers of DCLK1 + cells (Fig. 3e). Pimozide treatment
also reduced the expression of CD44, CD133, Oct-4, and
ABCG2 levels in both monolayer and 3D osteospheres
cultures in both KHOS/NP and SJSA-1 cells (Fig. 3c, d).
Taken together, these data suggest that pimozide treatment affects osteosarcoma stem cells.
Pimozide inhibits STAT5 signaling

Previous studies have suggested that pimozide inhibits
STAT3 and STAT5 signaling10,36. However, the precise
mechanism of the inhibition is not known. These STAT
genes encode proteins required for self-renewal, cell
survival and proliferation37. Pimozide inhibits STAT3
phosphorylation resulting in suppression expression of
target genes BclXL, Mcl1 and Myc in hepatocellular carcinoma38. Previous studies have also shown that although
pimozide decreases STAT5 tyrosine phosphorylation,
although it does not suppress tyrosine kinases10. Using the
crystal structure for STAT5A (PDB:1Y1U) and STAT5B
(PDB: 6MBW), we performed homology modeling to
determine how pimozide interacts with the proteins39,40.
We chose the region for our studies because the activating
phosphorylation site in STAT5A and STAT5B are Tyr694
and Tyr699, respectively41. Pimozide demonstrated strong
binding to both STAT5A and STAT5B (Fig. 4a). The
binding energies for STAT5A and STAT5B were predicted to be −8.4 kcal/mol and −6.4 kcal/mol, respectively (Fig. 4a). A key anchoring amino acid in both
proteins is Asn642, which has been shown to be mutated
in some cancers40. To further conﬁrm their binding in
cells, we performed cellular thermal shift assays (CETSA)
to assess protein stability. For this, KHOS/NP cells were
incubated with pimozide for 4 h at room temperature, and
subsequently subjected to increasing temperatures from
40 to 59 °C. Western blot analyses demonstrated that
thermal denaturation of STAT5 in control, DMSO cells
occurs at 46 °C. However, following pimozide treatment,
the denaturation temperature changed to 55 °C (Fig. 5b).
On the other hand, the compound did not affect the
stability of GAPDH. This suggests that pimozide speciﬁcally binds and provides stabilization of STAT5 protein in
the cells. We also determined whether pimozide interaction with the STAT5 affects phosphorylation, especially
because the compound was found to interact with speciﬁc
amino acids around the phosphorylation site. There was a

Subramaniam et al. Cell Death and Disease (2020)11:149

Fig. 3 (See legend on next page.)
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(see ﬁgure on previous page)
Fig. 3 Pimozide affects cancer stem cell marker expression. a KHOS/NP and SJSA-1 cells were grown in speciﬁc spheroid media in low adherent
plates and treated with 0–25 μM of pimozide. After 5 days, the spheroids were photographed and counted. Scale bars represent 100 μm. b Primary
spheroids were collected and separated into single cells and re-plated. Pimozide treatment signiﬁcantly inhibited osteosphere formation (*p < 0.05). c
and d Western blot analyses of lysates from 3D cultures showed signiﬁcant increase of DCLK1 short form in both KHOS/NP and SJSA-1 cells when
compared to 2D cultures. Pimozide inhibits the expression of the DCLK1 isoforms. Western blot analyses of lysates from 3D cultures showed
signiﬁcant increase of CD44, CD133, Oct-4, and ABCG2 levels in both KHOS/NP and SJSA-1 cells when compared to 2D cultures which was
suppressed by pimozide. e Sorting of anti-DCLK1 antibody-tagged phycoerythrin in KHOS/NP and SJAS-1 cells by ﬂow cytometry. After 24 h,
pimozide treatment resulted in a signiﬁcant reduction in the number of DCLK1 positive cells.

signiﬁcant reduction in both phosphorylation of STAT5
protein (Fig. 4c) In addition, there was a reduction in the
phosphorylation of STAT3 and ERK1/2 MAP kinase following pimozide treatment (Fig. 4c). These data suggest
that pimozide inhibits STAT-3 and -5 phosphorylation
and its downstream signaling.
STAT5 protects cells from pimozide-mediated cell death

Previous studies suggested that pimozide is a STAT5
inhibitor10,42. To determine the role of STAT5 in pimozide mediated OS cell death, we used speciﬁc silencer
RNAs for STAT5A and STAT5B to downregulate these
proteins in KHOS/NP cells (Fig. 5a). However, the antibodies used to detect total protein and the phosphorylated
form recognize both STAT5A and STAT5B. Nevertheless,
the western blot suggests that there is higher levels of
STAT5B in the cells compared to STAT5A. Cell cycle
analyses demonstrated that this did not signiﬁcantly
change cell cycle progression of the cells (Fig. 5b). However, there was about 35% reduction in proliferation at
baseline in the STAT5A and STAT5B knocked down cells
(Fig. 5c). Moreover, in cells treated with pimozide there
was a further reduction in the proliferation of the cells,
and this did not change with the levels of STAT5A or
STAT5B (Fig. 5c). We next determined the effect of
suppressing STAT5 expression on pimozide mediated
apoptosis. While suppressing STAT5A or STAT5 did not
induce cleavage mediated activation of caspase 3, treatment with pimozide following STAT5A or STAT5
knockdown signiﬁcantly induced caspase 3 cleavage (Fig.
5d). This suggests that STAT5 may protect cells from
pimozide induce cell death. To conﬁrm this, we next
performed ﬂow cytometry studies. We treated KHOS/NP
and SJSA-1 cells with 10 µM pimozide and subsequently
determined phosphatidylserine externalization in apoptotic cells using recombinant annexin V conjugated to
green-ﬂuorescent FITC dye. In addition, to identify dead
cells, we stained the cells with propidium iodide (PI).
While apoptotic cells will produce green ﬂuorescence,
dead cells would give red ﬂuorescence. Flow cytometry
analyses suggested that just knockdown of STAT5A or
STAT5B demonstrated no changes in cell undergoing
necrosis and apoptosis (Fig. 5e). However, following
Ofﬁcial journal of the Cell Death Differentiation Association

pimozide treatment there was signiﬁcantly increased
levels of necrosis and apoptosis in KHOS/NP cells (Fig.
5e). In addition, there was also an interesting difference
observed between cells where STAT5A or STAT5B was
knocked down. While cells in which STAT5A was
knocked down, the effects of pimozide was similar to that
seen in with controls, knockdown of STAT5B resulted in
reduced levels of pimozide mediated necrosis, and a
corresponding increase in late apoptosis (Fig. 5e). These
data suggest that STAT5B may protect the cells from
pimozide mediated apoptosis.
Pimozide inhibits growth of KHOS/NP tumor xenografts

To evaluate the role of pimozide on tumor growth
in vivo, we examined tested the compound on subcutaneous growth of OS xenografts. KHOS/NP cells were
injected into the ﬂanks of athymic nude mice, and
xenograft tumors were allowed to develop. After one
week, pimozide was administered intraperitoneally at a
dose of 10 mg/kg bw daily for three weeks (Fig. 6a, b).
There was no signiﬁcant difference observed in the animal
weights following treatment with pimozide (Fig. 6c).
Pimozide treatment signiﬁcantly inhibited the growth of
tumor xenografts, resulting in reduced tumor volumes
(p < 0.001) (Fig. 6e). The excised tumors from control
animals weighed ~1700 mg, while those from animals
treated with pimozide weighed ~300 mg (p < 0.004) (Fig.
6d). There was no apparent change in liver and spleen
weight in the animals (data not shown). These data imply
that pimozide is a potential therapeutic agent for treating
OS with relatively non-toxic effects to the animals.
Pimozide suppresses STAT5 signaling and OS stem cell
marker expression in tumor xenograft tissues

Since we observed a reduction in cyclin D1 in the
in vitro cell culture studies, we determined the effect of
pimozide treatment on cyclin D1 expression in the
xenograft tissues. Western blot and immunohistochemistry analyses demonstrated that pimozide treatment signiﬁcantly reduced cyclin D1 levels when compared to
controls (Fig. 7a, b). Next, we determined whether
pimozide affected OS stemness by looking for expression
of speciﬁc stem cell marker proteins. Both western blot
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Fig. 4 Pimozide inhibits STAT5 phosphorylation. a Pimozide interacts with the STAT5. We performed molecular docking and determined that
pimozide can interact with the SH2 domain of STAT5A and STAT5B with binding energy of −8.4 and −6.4 kcal/mol, respectively. b Cellular thermal
shift assay (CETSA). KHOS/NP cells were treated with pimozide and subjected to differential temperature treatment for 3 mins. Resulting lysates were
subjected to western blot analyses for STAT5. Pimozide protected STAT5 against thermal denaturation suggesting that pimozide-STAT5 interaction. c
Lysates from pimozide treated cells caused a signiﬁcant decrease in the phosphorylation of STAT5, STAT3, and ERK.

and immunohistochemistry analyses demonstrated that
pimozide treatment signiﬁcantly reduced the levels of OS
stem cells marker proteins DCLK1, CD44, and ABCG2
when compared to controls (Fig. 7c, d). These data suggest that pimozide targets OS stem cells with high
Ofﬁcial journal of the Cell Death Differentiation Association

potency. Furthermore, we observed a signiﬁcant reduction
in STAT5 phosphorylation in the xenograft tissues (Fig.
7e, f). These data suggest that pimozide inhibits cell
proliferation, as well as OS stem cells in the tumor
xenograft tissues.

Subramaniam et al. Cell Death and Disease (2020)11:149

Fig. 5 (See legend on next page.)

Ofﬁcial journal of the Cell Death Differentiation Association

Page 9 of 15

Subramaniam et al. Cell Death and Disease (2020)11:149

Page 10 of 15

(see ﬁgure on previous page)
Fig. 5 STAT5 protects cells from pimozide-mediated cell death. a Cells were transfected with siRNA for STAT5A, STAT5B or both for 72 h. Lysates
were analyzed STAT5 western blot. Knockdown of STAT5A or STAT5B reduced STAT5 protein levels, with greater reduction observed in cells
transfected with STAT5B. b Cells were transfected with siRNA for STAT5A, STAT5B or both for 48 h, and subsequently subjected to ﬂow cytometry
following staining with propidium iodide. Knockdown of STAT5 protein did not affect cell cycle progression of OS cells. c Cells transfected with siRNA
to STAT5A, STAT5B or both were treated with 10 µM pimozide. Cell proliferation measured by hexosaminidase assay demonstrated that knockdown
of STAT5 reduced cell proliferation. d Cells were transfected with siRNA for STAT5A, STAT5B or both for 48 h and then treated with 10 µM pimozide
for 24 h. Lysates were analyzed for STAT5 and Caspase 3 levels. Knockdown of STAT5A or STAT5B further enhanced pimozide mediated caspase 3
cleavage. e Cells were transfected with siRNA to STAT5A, STAT5B or both and then treated with pimozide were analyzed by ﬂow cytometry following
AnnexinV/PI staining. Pimozide treatment signiﬁcantly induced cells to undergo necrosis and late apoptosis. However, knockdown of STAT5B
reduced pimozide mediated necrosis resulting in further increase in apoptosis.

Discussion
STAT5 has been shown to be a key player in tumor cell
survival, proliferation and invasion43. However, although
suppressing JAK/STAT signaling appears to be a promising strategy in inhibiting tumor growth, targeting the
protein has been rather difﬁcult. Small molecules have
been developed that targets the SH2 domain including
pimozide, which has shown some promise against acute
myelogenous leukemia42. Given the high STAT5 activity
in OS cells, we tested the effect of the compound and see
high activity. Pimozide is an antipsychotic FDA-approved
drug used to treat neuroleptic disorders. Pimozide had
relatively low side-effect and exhibits a broad spectrum of
molecular targets including monosymptomatic hypochondriacal psychoses, body dysmorphic disorder, metastatic melanoma, trichotillomania, and trigeminal and
postherpetic neuralgia44. Pimozide has been shown to
inhibit the growth of various cancer cells including
prostate cancer, lung, breast, colon, liver, glioblastoma
and leukemia6,45. These studies suggest that pimozide
could be used as an effective chemotherapeutic agent. Our
results also indicate that the pimozide has a signiﬁcant
potential in the treatment of OS.
Previous studies have suggested that pimozide is a
STAT5 inhibitor although the mechanism by which the
inhibition works is not well understood42. Our studies
demonstrate that pimozide interacts with Asn642.
Mutations at Asn642 is a common oncogenic driver
mutation that promotes aggressive T-cell leukemia/lymphoma40. Since pimozide binds to this site in STAT5B,
suggests that masking this site may be important to
suppress the protein function. Similarly, it is interesting
that STAT5B may protect the cells by sequestering the
compound, and knockdown of the protein therefore
enhances pimozide activity against the cell. This might
one reason for why targeting the protein in cancer cells
have been difﬁcult.
Pimozide appears to inhibit many of the characteristic
cancer-promoting events. Previous studies demonstrated
that pimozide inhibits cell proliferation and induces ROS
generation in human OS by suppressing catalase expression36. Previously, we have suggested that natural
Ofﬁcial journal of the Cell Death Differentiation Association

compounds targeting major cell signaling pathways may
be a novel paradigm for OS therapy including Wnt, Notch,
Hedgehog, Hippo, and JAK-STAT signaling pathways25,46.
CSCs have the capacity to drive tumor resistance and
recurrence to chemotherapeutic agents37,47. Pimozide has
been previously shown to suppress stem-like cell maintenance and tumorigenicity in hepatocellular carcinoma36.
Indeed, our results suggest that the pimozide is a potent
inhibitor of OS stem cells. The compound suppressed
expression of known OS stem cell markers CD44, CD133,
Oct-4, and ABCG2, both in cells grown as 2D cultures and
in osteospheres. Moreover, we have now identiﬁed that
DCLK1, a reserve quiescent stem cell marker in both the
normal intestinal epithelium and in colon cancers18,19 is
also expressed in OS cells. More importantly, the short
variant of DCLK1 is upregulated in osteospheres, and this
is suppressed in response to pimozide. Hence, targeting
these cells with pimozide appears to be a promising
approach for the treatment of OS.
In conclusion, the current studies provide evidence that
pimozide is able to suppress the growth of OS stem and
progenitor cells, and that this may in part through suppressing STAT5 activity. Hence, the compound or its
derivatives may be of interest as a therapeutic for OS
either alone or in combination with current standard
therapeutics. Additional studies are required as a follow
up to the studies presented in this manuscript to further
move the compound or its analog to the clinic for the
treatment of patients with OS.

Methods
Cell lines and reagents

KHOS/NP, MG63, and SJSA-1 human OS cells
(American Type Culture Collection, Manassas, VA) were
grown in DMEM containing 10% heat-inactivated fetal
bovine serum (Sigma-Aldrich, St. Louis, MO, USA) and
2% antibiotic-antimycotic solution (Corning Life Sciences,
Oneonta, NY, USA) at 37 °C in a humidiﬁed atmosphere
containing 5% CO2. The studies were performed with
cells within 20 passages after receipt or resuscitation
(~3 months of non-continuous culturing). We authenticated the cell lines by STR allele proﬁling by an
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Fig. 6 Pimozide inhibits KHOS/NP induced osteosarcoma tumor xenograft growth. a Experimental plan, b KHOS/NP cells were injected in to
the ﬂanks of nude mice and palpable tumors were allowed to develop for 7 days. Subsequently, pimozide (10 mg/kg bw) was injected daily
intraperitoneally every day for 21 days. Tumor size was measured every week. On day 22, tumors were excised and subject to further analyses. c
Pimozide treatment did not reduced the animal weight. d Tumor weight in pimozide treated mice were smaller when compared to control (*P <
0.004). e Pimozide treatment signiﬁcantly reduced tumor volumes (*P < 0.001). Error bars represent means ± SEM (N = 5 for each group). *P < 0.05,
Student’s t-test.

independent source (NIH-funded University of Arizona
Genetics Core, Tucson, AZ-Cell line Authentication
Core). Eighty percent homology demonstrates validity of
the cell lines. We tested cell lines for mycoplasma.
Pimozide was obtained from Sigma-Aldrich and dissolved
in dimethyl sulfoxide (DMSO).
Proliferation assay

To assess proliferation, the cells were seeded on to 96
well plates and grown overnight. Thereafter, the cells were
treated with increasing doses of pimozide (0–40 µM) in
Ofﬁcial journal of the Cell Death Differentiation Association

DMEM containing 10% FBS. Analysis of cell proliferation
was performed by the enzymatic assay as previously
described48.
Colony formation assay

Brieﬂy, 6 well dishes were seeded with 500 viable cells
and allowed to grow for overnight. Thereafter, the cells
were incubated in the presence or absence of 0–10 µM
Pimozide for 48 h. Pimozide containing medium was then
removed, and the cells were washed in PBS and incubated
for an additional 10 days in complete DMEM medium.

Subramaniam et al. Cell Death and Disease (2020)11:149

Page 12 of 15

Fig. 7 Pimozide inhibits cyclin D1, cancer stem cell markers, and STAT5 signaling proteins in tumor xenograft tissues. a Western blot (C1,
C2, C3, C4 are control tumor xenograft tissues and P1, P2, P3, P4 are pimozide treated tumor xenograft tissues) and b immunohistochemistry analyses
showed that tissue lysates from pimozide treated animals have signiﬁcantly lower levels of cyclin D1 expression. Scale bars represent 40 μm. c
Western blot (C1, C2, C3, C4 are control tumor xenograft tissues and P1, P2, P3, P4 are pimozide treated tumor xenograft tissues) and d
immunohistochemistry analyses showed that tissue lysates from pimozide treated animals have signiﬁcantly lower expression levels of cancer stem
cell markers DCLK1, CD44 and ABCG2. Scale bars represent 40 μm. e Western blot (C1, C2, C3, C4 are control tumor xenograft tissues and P1, P2, P3,
P4 are pimozide treated tumor xenograft tissues) and f immunohistochemistry analyses showed that tissue lysates from Pimozide treated tumor
tissues as signiﬁcantly reduced the phosphorylation of STAT5. Scale bars represent 40 μm.

Each treatment was done in triplicate. The colonies
obtained were washed with PBS and ﬁxed in 10% formalin
for 15 min at room temperature and then washed with
PBS followed by staining with Crystal violet. The colonies
were counted and compared with the untreated cells.
Tumor in A Dish (TiD)

1000–2000 cells each of normal human lung epithelial
cells, normal human lung ﬁbroblasts, human umbilical
Ofﬁcial journal of the Cell Death Differentiation Association

vein endothelial cells and normal lymphatic endothelial
cells were mixed with KHOS/NP GFP positive cells and
grown in an ultra-low attachment using speciﬁc spheroid
media27. Once the organoid had developed, it was treated
with Pimozide. After 5 days of treatment, the organoids
were assessed by Nikon Eclipse Ti microscope under a
×40 objective. Subsequently, the cells were separated and
the number of GFP + KHOS/NP cells were determined by
ﬂow cytometry. Flow cytometry was done with a
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FACSCalibur analyzer (Becton Dickinson, Mountain,
View, CA, USA), capturing 10,000 events for each sample.
Results were analyzed with ModFit LT™ software (Verity
Software House, Topsham, ME).

increasing concentrations of pimozide (0–25 μM). After
5 days the spheroids were photographed. For second
passages, the primary spheroids were dissociated with
trypsin, and cells were grown in the absence of pimozide.

Cell cycle analyses

Molecular docking

Cells were treated with 20 µM of pimozide for up to
48 h. Thereafter, the cells were trypsinized and suspended
in phosphate-buffered saline (PBS). Single-cell suspensions were ﬁxed using 70% ethanol for overnight, and
subsequently permeabilized with PBS containing 1 mg/
mL propidium iodide (Sigma-Aldrich), 0.1% Triton X-100
(Sigma-Aldrich) and 2 µg DNase-free RNase (SigmaAldrich) at room temperature. Flow cytometry was done
as mentioned above.

The docking study was performed by using AutoDock
Vina software49 to study the interaction of Pimozide with
the crystal structure of STAT5 extracted from Protein
Data Bank (STAT5A (PDB:1Y1U) and STAT5B
(PDB:6MBW)) online database (www.rcsb.org/pdb)50.
The ligand molecules in the active site were removed and
the 3-D grid box was created with grid center coordinates
and 60 × 60 × 60 point size covering all active site residues
within it. All the docking studies were executed based on
default parameters of the Autodock Tools. Prior to
docking, the protein was prepared by adding hydrogens,
total Kollman and Gasteiger charges. Lamarckian GA was
used to search the best conformations. About 10 conformations for pimozide docked in the SH2 domain of
STAT5A or STAT5B were generated. Further, the most
stable conformation of pimozide was selected based on a
predicted score by the scoring function and the lowest
binding energy. The STAT5 docking conformation was
visualized with Pymol51.

Caspase3/7 assay

KHOS/NP and SJSA-1 cells grown in 96 well black
plates were treated with pimozide for up to 48 h. Caspase3/7 activity was examined using the Apo-ONE®
Homogeneous Caspase-3/7 Assay systems according to
the manufacturer’s instructions (Promega, Madison, WI).
Western blot analysis

Cell lysates were subjected to polyacrylamide gel electrophoresis, and then blotted onto Immobilin-P polyvinylidene diﬂuoride membranes (Millipore, Bedford,
MA). Antibodies for cyclin D1 (catalog # 2978), CDK2
(catalog # 2546), phospho-Rb (catalog # 8516), Rb (catalog
# 9309), PARP(catalog No # 9532), Caspase 3 (catalog #
9662), Bcl2 (catalog # 2876), BclXL (catalog # 2764), Bax
(catalog No # 5023), CD44 (catalog # 3570), CD133
(catalog # 64326), phospho-STAT5 (catalog #s 4332,
9359), STAT5 (catalog # 25656), phospho-STAT3 (catalog # 9131), STAT3 (catalog # 4904), phospho-ERK
(catalog # 4370) and ERK (catalog # 9102), ABCG2 (catalog #42078), DCLK1 (catalog # 62257) were purchased
from Cell Signaling Technology (Danvers, MA, USA), for
DCLK1 (catalog # ab37994), Oct-4 (catalog # ab189857)
from Abcam Inc. (Cambridge, MA, USA), CDK4 (catalog
# MA5–13498), CDK6 (catalog # MA5–13338) from
Thermoﬁsher (Waltham, MA, USA) and DCLK1 (catalog
# SAB2420186) and Actin (catalog # A1978) from Sigma
Aldrich and GAPDH (catalog # sc-365062) Santacruz
Biotechnology Inc (Santa Cruz, CA, USA). Speciﬁc proteins were detected by chemiluminescence system.

Cellular thermal shift assay (CETSA)

The ability of pimozide to interact with STAT5 in cells
was studied by CETSA52. Brieﬂy, KHOS/NP cells were
cultured and grown to 70–80% conﬂuency. Cells were
detached with trypsin, collected by centrifugation, washed
with PBS and subsequently resuspended in DMEM media
for counting. The cell suspension is treated with media
containing DMSO or pimozide (20 μM) for 4 h. After
treatment, the cell suspension was aliquoted into PCR
tubes and heated for 3 min at different temperature gradient. Subsequently, cells were lysed using two repeated
freeze-thaw cycles using liquid nitrogen followed by
centrifugation for 20 min. The resultant proteins were
diluted with 4× Laemmli buffer, boiled at 70 °C for 10 min
and loaded onto 10% SDS-PAGE gel, transferred to PVDF
membrane and incubated with STAT5 antibody from Cell
Signaling at a concentration of 1:500. Protein levels on
western blot were pictured by Bio-Rad ChemiDoc-XRS +
instrument and analyzed by image lab software.
siRNA

Spheroid assay

Cells were cultured in DMEM supplemented with
20 ng/mL bFGF (Invitrogen) 10 mL per 500 mL of 50×
B27 supplement (Invitrogen) EGF 20 ng/mL (Invitrogen)
and antibiotics and antimycotic solution. Cells were seeded at low densities (2000 cells/mL) in 24 well low
adhesion plates. Thereafter, the cells were treated with
Ofﬁcial journal of the Cell Death Differentiation Association

STAT5A siRNA ID s13534 (locus ID 6776) sequence
was ACAGAACCCUGACCAUGUAtt, STAT5B siRNA
ID s13538 (locus ID 6777) sequence was CACCCGC
AAUGAUUACAGUtt and a scrambled control siRNA
not matching any of the human genes were obtained from
ThermoFisher Scientiﬁc, USA and transfected using
siPORT™ NeoFX™ Transfection Agent (ThermoFisher
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Scientiﬁc, USA). Brieﬂy, KHOS/NP cells were split and
added to the 96 or 6 well plates and immediately transfected with 100 nM siRNA and after 72 h measured for
cell proliferation or 48 h measured for cell cycle analysis.
After 36 h the KHOS/NP or SJSA-1 cells were treated
with pimozide for 24 h. Subsequently, western blot analysis or Annexin V/FITC ﬂow cytometry was performed.
Annexin V/PI staining

Brieﬂy, KHOS/NP cells were split and added to the 6
well plates and immediately transfected with 100 nM
siRNA. After 36 h the cells were treated with pimozide for
24 h. Thereafter, the cells were trypsinized and suspended
in ice cold phosphate-buffered saline (PBS). For Annexin
V/PI staining, ﬂow cytometry was performed using dead
cell apoptosis kit with Annexin V FITC and PI solution
(Thermo Fisher Scientiﬁc, Waltham, MA) as per the
manufacturer instructions. Results were analyzed with
FlowJo software.
KHOS/NP xenograft tumors in mice

Seven-week-old male athymic nude mice (N = 5 per
group), purchased from Charles Rivers Laboratory were
utilized for in vivo experiments. They were maintained
with water and standard mouse chow ad libidum and used
in protocols approved by the University’s Animal Studies
Committee. Animals were injected with 1 × 106 KHOS/
NP cells in the left and right ﬂank and allowed to form
xenograft. One week following implantation, and after
observing the presence of a palpable tumor, pimozide
(10 mg/kg body weight mixed with 25 mM phosphate
buffer in 50 mM captisol) was administered intraperitoneally daily for 21 days. Tumors were measured weekly
by blinded observer. At the end of treatment, the animals
were euthanized, and the tumors were removed, weighed
and used for histology, immunohistochemistry, and western blot analysis.
Immunohistochemistry

Parafﬁn-embedded tissues were cut to 4 µm sections,
deparafﬁnized and blocked with Avidin/Biotin for 20 min.
The slides were incubated with primary antibodies for
overnight at 4 °C. Next the slides were treated with broadspectrum secondary antibody (Invitrogen) and HRPconjugate for 1 h and then developed with DAB (Invitrogen). Finally, the slides were counterstained with
hematoxylin. The slides were examined in Nikon Eclipse
Ti microscope under a ×40 objective.
Statistical analysis

All values are expressed as the mean ± SEM. Data was
analyzed using an unpaired 2-tailed t test. A P value of less
than 0.05 was considered statistically signiﬁcant.
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